(Reuters) -Eli Lilly raised its full-year profit and revenue forecasts on Thursday as strong appetite for its widely popular weight-loss and diabetes drugs Zepbound and Mounjaro helped it breeze past third-quarter earnings estimates. Shares of the world's largest healthcare firm by market capitalization jumped over 5% in premarket trading even as investors remain wary of drug price negotiations with the Trump administration. Lilly competes with Novo Nordisk for the top spot in the weight-loss drug market ...